In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate

Pharmaceutical Research

Volumn 20, Issue 3, 2003, Pages 442-447

  Desai, Tejas R ^a   Tyrrell, Gregory J ^a   Ng, Tina ^a   Finlay, Warren H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aerosols; Liposomes; Lung deposition simulation; Nebulization efficiency; Polymyxin B sulfate

Indexed keywords

COLISTIMETHATE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; LIPOSOME; POLYMYXIN B LIPID COMPLEX; POLYMYXIN DERIVATIVE; POLYSORBATE 80; SORBITAN LAURATE; SURFACTANT; UNCLASSIFIED DRUG;

AEROSOL; AIRWAY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EVALUATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MUCUS; NEBULIZATION; NEBULIZER; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; FORECASTING; LIPOSOMES; LUNG; MATHEMATICS; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; RESPIRATORY MUCOSA; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 12244279936     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022664406840     Document Type: Article

References (30)

1. T. B. May, D. Shinabarger, R. Maharaj, J. Kato, L. Chu, and J. D. DeVault. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patient. Clin. Microbiol. Rev. 4:191-206 (1991).
2. B. van Klingeren. Antibiotic resistance in Pseudomonas aeruginosa, Haemophilus influenza and Staphylococcas aureus. Chest 94:S103-S109 (1988).
3. D. J. Touw, R. W. Brimicombe, M. E. Hodson, H. G. M. Heijerman, and W. Bakker. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 8:1594-1604 (1995).
4. D. R. Storm, K. S. Rosenthal, and P. E. Swnason. Polymyxin and related peptide antibiotics. Ann. Rev. Biochem. 46:723-763 (1977).
5. T. Jensen, S. S. Pedersen, S. Garne, C. Heilmann, N. Hoiby, and C. Koch. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19:831-838 (1987).
6. M. E. Evans, D. J. Feola, and R. P. Rapp. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram negative bacteria. Ann. Pharmacother. 33:960-967 (1999).
7. H. Schreier, R. J. Gonalez-Rothi, and A. A Stecenko. Pulmonary delivery of liposomes. J. Control. Release 24:209-223 (1993).
8. W. A. Craig and C. M. Kunin. Dynamics of binding and release of the polymyxin antibiotics by tissues. J. Pharmacol. Exp. Ther. 184:757-765 (1973).
9. S. M. McAllister, H. O. Alper, Z. Teitelbaum, and D. B. Bennette. Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung? Adv. Drug Deliv. Rev. 19:89-110 (1996).
10. J. N. Weinstein and L. D. Leserman. Liposomes as drug carriers in cancer chemotherapy. Pharmacol. Ther. 24:207-233 (1984).
11. G. Gregoriadis. Liposomes as Drug Carriers. J. Wiley & Sons, London, 1988.
12. S. M. McAllister, H. O. Alper, and M. R. W. Brown. Antimicrobial properties of liposomal polymyxin B. J. Antimicrob. Chemother. 43:203-210 (1999).
13. F. Morén and S. P. Newman. Aerosol dosage forms and formulations. In: F. Morén, M. B. Dolovich, and M. T. Newhouse (Eds.), Aerosols in Medicines. Elsevier, New York, 1993, p.321.
14. W. H. Finlay. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction. Academic Press, Oxford, 2001.
15. C. Beaulac, S. Sachetelli, and J. Lagace. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J. Drug Target. 7:33-41 (1999).
16. J. Krzek, M. Starek, A. Kwiecien, and W. Rzeszutko. Simultaneous identification and quantitative determination of neomycin sulfate, polymixin B sulfate, zinc bacytracin and methyl and propyl hydroxybenzoates in ophthalmic ointment by TLC. J. Pharm. Biomed. Anal. 24:629-636 (2001).
17. W. H. Finlay, C. F. Lange, M. King, and D. P. Spreet. Lung delivery of aerosolized dextran. Am. J. Respir. Crit. Care Med. 161:91-97 (2000).
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 2nd ed.: Approved Standard M7-A2, NCCLS, Villanova, Pennsylvania, 1990.
19. R. M. Prokop, W. H. Finlay, and K. W. Stapleton. An in vitro technique for calculating the regional dosages of drugs delivered by an ultrasonic nebulizer. J. Aerosol Sci. 26:847-860 (1995).
20. J. G. Widdicombe. Airways surface liquid: Concepts and measurements. In D. F. Rogers and M. I. Lethem (eds). Airway Mucus: Basic Mechanism and Clinical Perspectives, Birkhauser, Basel, 1997, pp. 1-17.
21. C. G. Phillips, S. R. Kaye, and R. C. Schroter. A diameter-based reconstruction of the breathing pattern of the human bronchial tree. Part I. Description and application. Resp. Physiol. 98:193-217 (1994).
22. B. Haefeli-Bleuer and E. R. Weibel. Morphometry of the human pulmonary acinus. Anat. Rec. 220:401-414 (1988).
23. D. B. Yeates, J. M. Sturgess, S. R. Kahi, H. Levison, and N. Aspin. Mucociliary transport in trachea of patients with cystic fibrosis. Arch. Dis. Childhood 51:28-33 (1975).
24. B. Oberwaldner, J. C. Evans, and M. S. Zach. Forced expirations against a variable resistance: A new chest physiotherapy method in cystic fibrosis. Pediatr. Pulmonol. 2:358-367 (1986).
25. C. F. Lange, R. E. W. Hancock, J. Samuel, and W. H. Finlay. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J. Pharm. Sci. 90:1647-1657 (2001).
26. T. R. Desai, J. P. Wong, R. E. W. Hancock, and W. H. Finlay. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J. Pharm. Sci. 91:482-491 (2002).
27. S. B. Kulkarni, G. V. Betagiri, and M. Singh. Factors affecting microencapsulation of drug in liposomes. J. Microencapsul. 12:229-246 (1995).
28. A. Omri, M. Ravaoarinoro, and M. Poisson. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 36:631-639 (1995).
29. P. Diot, P. F. Dequin, B. Rivoire, F. Gagnadoux, F. Faurisson, E. Diot, E. Boissinot, A. Le Pape, L. Palmer, and E. Lemarie. Aerosols and anti-infectious agents. J. Aerosol Med. 14:55-64 (2001).
30. S. L. Katz, S. L. Ho, and A. L. Coates. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest 119:250-255 (2001).